In the past week, ENSC stock has gone down by -18.37%, with a monthly decline of -41.33% and a quarterly plunge of -51.98%. The volatility ratio for the week is 8.20%, and the volatility levels for the last 30 days are 8.03% for Ensysce Biosciences Inc The simple moving average for the past 20 days is -28.22% for ENSC’s stock, with a -66.31% simple moving average for the past 200 days.
Is It Worth Investing in Ensysce Biosciences Inc (NASDAQ: ENSC) Right Now?
The 36-month beta value for ENSC is at 0.86. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ENSC is 11.01M, and currently, shorts hold a 1.85% of that float. The average trading volume for ENSC on October 01, 2024 was 1.80M shares.
ENSC) stock’s latest price update
Ensysce Biosciences Inc (NASDAQ: ENSC)’s stock price has dropped by -16.67 in relation to previous closing price of 0.29. Nevertheless, the company has seen a loss of -18.37% in its stock price over the last five trading days. accesswire.com reported 2024-09-27 that SAN DIEGO, CA / ACCESSWIRE / September 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has received notice from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) stating that the Company has not regained compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock has remained below $1.00 per share through the initial 180-day compliance period ended September 23, 2024. The Company is not eligible for a second 180-day period because it does not comply with the minimum stockholders’ equity requirement for initial listing on The Nasdaq Capital Market.
ENSC Trading at -38.64% from the 50-Day Moving Average
After a stumble in the market that brought ENSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.35% of loss for the given period.
Volatility was left at 8.03%, however, over the last 30 days, the volatility rate increased by 8.20%, as shares sank -39.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.83% lower at present.
During the last 5 trading sessions, ENSC fell by -18.37%, which changed the moving average for the period of 200-days by -77.78% in comparison to the 20-day moving average, which settled at $0.3266. In addition, Ensysce Biosciences Inc saw -77.36% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENSC
Current profitability levels for the company are sitting at:
- -6.72 for the present operating margin
- -2.72 for the gross margin
The net margin for Ensysce Biosciences Inc stands at -7.84. The total capital return value is set at -6.49. Equity return is now at value -380.55, with -246.41 for asset returns.
Based on Ensysce Biosciences Inc (ENSC), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -21.83. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is -5.93.
Currently, EBITDA for the company is -10.72 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 1.47. The receivables turnover for the company is 6.41for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.88.
Conclusion
In conclusion, Ensysce Biosciences Inc (ENSC) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
